Floatz logo

44 assets in Hepatoblastoma

Therapeutic assets addressing Hepatoblastoma, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Cyclophosphamide
Hepatoblastoma
St. Jude Children's Research HospitalP2BB (66)
Etoposide
Hepatoblastoma
Children's Oncology GroupP3BB (66)
(+)-Vincristine
Hepatoblastoma
University of BirminghamP3BB (66)
Carboplatin
Hepatoblastoma
Children's Oncology GroupP3BB (64)
Oxaliplatin
Hepatoblastoma
Children's Oncology GroupP3B (62)
Adriamycin
Hepatoblastoma
Children's Oncology GroupP3B (60)
Cis-Diamminedichloroplatinum Ii
Hepatoblastoma
Children's Oncology GroupP3B (60)
Fluorouracilum
Hepatoblastoma
Children's Oncology GroupP3B (60)
Irinotecan
Hepatoblastoma
Children's Oncology GroupP3B (60)
Sorafenib
Hepatoblastoma
Children's Oncology GroupP3B (60)
Vincristine Sulfate
Hepatoblastoma
Children's Oncology GroupP3B (60)
Ipilimumab
Hepatoblastoma
Children's National Research InstituteP2B (57)
Nivolumab
Hepatoblastoma
Instituto do Cancer do Estado de São PauloP2B (57)
Olaparib
Hepatoblastoma
National Cancer Institute (NCI)P2B (57)
Palbociclib
Hepatoblastoma
National Cancer Institute (NCI)P2B (57)
PI3K/MTOR INHIBITOR LY3023414
Hepatoblastoma
National Cancer Institute (NCI)P2B (57)
Tazemetostat
Hepatoblastoma
National Cancer Institute (NCI)P2B (57)
Vemurafenib
Hepatoblastoma
National Cancer Institute (NCI)P2CCC (55)
2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)-
Hepatoblastoma
National Cancer Institute (NCI)P2CCC (53)
Cabozantinib
Hepatoblastoma
National Cancer Institute (NCI)P2CCC (53)
Ensartinib
Hepatoblastoma
National Cancer Institute (NCI)P2CCC (53)
Ivosidenib
Hepatoblastoma
National Cancer Institute (NCI)P2CCC (53)
Larotrectinib
Hepatoblastoma
National Cancer Institute (NCI)P2CCC (53)
Pan-Fgfr Tyrosine Kinase Inhibitor Jnj-42756493
Hepatoblastoma
National Cancer Institute (NCI)P2CCC (53)
Selpercatinib
Hepatoblastoma
National Cancer Institute (NCI)P2CCC (53)
Selumetinib
Hepatoblastoma
National Cancer Institute (NCI)P2CCC (53)
Ulixertinib
Hepatoblastoma
National Cancer Institute (NCI)P2CCC (53)
Mesna
Hepatoblastoma
St. Jude Children's Research HospitalP1/2CCC (52)
Onivyde
Hepatoblastoma
St. Jude Children's Research HospitalP1/2CCC (48)
Talazoparib
Hepatoblastoma
St. Jude Children's Research HospitalP1/2CCC (48)
Tegavivint
Hepatoblastoma
Children's Oncology GroupP1/2CCC (48)
Cobolimab
Hepatoblastoma
GlaxoSmithKlineP1/2CC (47)
Dostarlimab
Hepatoblastoma
GlaxoSmithKlineP1/2CC (47)
et140203 t cells
Hepatoblastoma
Eureka Therapeutics Inc.P1/2CC (47)
21.15.gpc3-car t cells
Hepatoblastoma
Baylor College of MedicineP1CC (43)
b7-h3 car t cells
Hepatoblastoma
St. Jude Children's Research HospitalP1CC (43)
Fludarabine
Hepatoblastoma
St. Jude Children's Research HospitalP1CC (43)
Pembrolizumab
Hepatoblastoma
Seattle Children's HospitalP1CC (43)
Sc-Car.Gpc3Xil15.21 Car T Cells
Hepatoblastoma
Seattle Children's HospitalP1CC (43)
Second Generation 4-1Bbζ B7H3-Egfrt-Dhfr
Hepatoblastoma
Seattle Children's HospitalP1CC (43)
Second Generation 4-1Bbζ Egfr806-Egfrt
Hepatoblastoma
Seattle Children's HospitalP1CC (43)
Second Generation 4-1Bbζ Egfr806-Egfrt And A Second Generation 4 1Bbζ Cd19-Her2Tg
Hepatoblastoma
Seattle Children's HospitalP1CC (43)
Val-413
Hepatoblastoma
Valent Technologies, LLCP1CC (43)
Vorinostat
Hepatoblastoma
New York Medical CollegeP1CC (43)